The role of Toll-like receptor mediated signalling in the pathogenesis of multiple myeloma

Critical Reviews in Oncology/Hematology

Volumn 80, Issue 2, 2011, Pages 225-240

  Abdi, Jahangir ^a   Engels, Ferdi ^a   Garssen, Johan ^a   Redegeld, Frank ^a  

^a UTRECHT UNIVERSITY   (Netherlands)

Author keywords

Apoptosis; B cell; Heat shock protein; Innate immunity; Malignant plasma cell; Multiple myeloma; Osteoclast; Toll like receptor

Indexed keywords

CPG OLIGODEOXYNUCLEOTIDE; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 6; MITOGEN ACTIVATED PROTEIN KINASE P38; OSTEOCLAST DIFFERENTIATION FACTOR; OSTEOPROTEGERIN; RECEPTOR ACTIVATOR OF NUCLEAR FACTOR KAPPA B; TOLL LIKE RECEPTOR; TOLL LIKE RECEPTOR 10; TOLL LIKE RECEPTOR 11; TOLL LIKE RECEPTOR 12; TOLL LIKE RECEPTOR 13; TOLL LIKE RECEPTOR 2; TOLL LIKE RECEPTOR 3; TOLL LIKE RECEPTOR 4; TOLL LIKE RECEPTOR 5; TOLL LIKE RECEPTOR 6; TOLL LIKE RECEPTOR 7; TOLL LIKE RECEPTOR 8; TOLL LIKE RECEPTOR 9; UNCLASSIFIED DRUG;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; BONE INFECTION; BONE METASTASIS; CANCER GROWTH; CANCER IMMUNOTHERAPY; CARCINOGENESIS; CELL PROLIFERATION; CELL SURVIVAL; CELLULAR DISTRIBUTION; CYTOGENETICS; HUMAN; HYPOXIA; IMMUNOMODULATION; IMMUNOSTIMULATION; INFLAMMATION; MULTIPLE MYELOMA; NONHUMAN; OSTEOLYSIS; PATHOPHYSIOLOGY; PROTEIN ANALYSIS; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN LOCALIZATION; PROTEIN PROTEIN INTERACTION; REVIEW; SIGNAL TRANSDUCTION; TISSUE DISTRIBUTION; TUMOR MICROENVIRONMENT; TUMOR VASCULARIZATION;

ANIMALS; B-LYMPHOCYTES; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MULTIPLE MYELOMA; SIGNAL TRANSDUCTION; TOLL-LIKE RECEPTORS;

EID: 79953674746     PISSN: 10408428     EISSN: 18790461     Source Type: Journal    
DOI: 10.1016/j.critrevonc.2010.12.001     Document Type: Review

References (145)

1. Kyle R.A., Rajkumar S.V. Multiple Myeloma. N Engl J Med 2004, 351:1860-1873.
2. Hideshima T., Mitsiades C., Tonon G., Richardson P.G., Anderson K.C. Understanding multiple myeloma pathogenesis in the bone marrow to identify new therapeutic targets. Nat Rev Cancer 2007, 7:585-598.
3. Paradisi F., Corti G., Cinelli R. Infections in multiple myeloma. Infect Dis Clin N Am 2001, 15(2):373-384.
4. Nucci M., Anaissie E. Infections in patients with multiple myeloma. Semin Hematol 2009, 46(3):277-288.
5. Akira Sh, Uematsu S., Takeuchi O. Pathogen recognition and innate immunity. Cell 2006, 124:783-801.
6. Whiteside T.L. Immune suppression in cancer: effects on immune cells, mechanisms and future therapeutic intervention. Semin Cancer Biol 2006, 16:3-15.
7. Huang B., Zhao J., Unkeless J.C., Feng Z.H., Xiong H. TLR signaling by tumor and immune cells: a double-edged sword. Oncogene 2008, 27:218-224.
8. Rakoff-Nahoum S., Medzhitov R. Toll-like receptors and cancer. Nat Rev Cancer 2009, 9(1):57-63.
9. Huang B., Zhao J., Li H., et al. Toll-like receptors on tumor cells facilitates evasion of immune surveillance. Cancer Res 2005, 65:5009-5014.
10. Liu J., Hamrouni A., Wolowiec D., et al. Plasma cells from multiple myeloma patients express B7-H1 (PD-L1) and increase expression after stimulation with IFN-γ and TLR ligands via a MyD88-, TRAF6-, and MEK-dependent pathway. Blood 2007, 110:296-304.
11. Jego G., Bataillie R., Geffroy-Leuseau A., Descamps G., Pellat-Deceunynck C. Pathogen-associated molecular patterns are growth and survival factors for human myeloma cells through Toll-like receptors. Leukemia 2006, 20:1130-1137.
12. Bohnhorst J., Rasmussen T., Moen S.H., et al. Toll-like receptors mediate proliferation and survival of multiple myeloma cells. Leukemia 2006, 20:1138-1144.
13. Chiron D., Jego G., Pellat-Deuceunynck C. Toll-like receptors: expression and involvement in multiple myeloma. Leukemia Res 2010, 10.1016/j.leukres.2010.06.002.
14. Xu Y., Zhao Y., Huang H., et al. Expression and function of toll-like receptors in multiple myeloma patients: Toll-like receptor ligands promote multiple myeloma cell growth and survival via activation of nuclear factor-κB. Brit J Haematol 2010, 150:543-553.
15. Li H., Hong S., Qian J., Zheng Y., Yang J., Yi Q. Crosstalk between the bone and immune systems: osteoclasts function as antigen-presenting cells and activate CD4+ and CD8+ T cells. Blood 2010, 116:210-217.
16. Lorenzo J., Horowitz M., Choi Y. Osteoimmunology: interactions of the bone and immune system. Endocr Rev 2008, 29(4):403-440.
17. Faure E., Thomas L., Xu H., Medvedev A.E., Equils O., Arditi M. Bacterial lipopolysaccharide and IFN-gamma induce Toll-like receptor 2 and Toll-like receptor 4 expression in human endothelial cells: role of NF-kappa in B activation. J Immunol 2001, 66:2018-2024.
18. Akiras Sh., Takeda K. Toll-like receptor signaling. Nat Rev Immunol 2004, 4:499-511.
19. Kawai T., Akiro Sh. Signalling to NFκB by Toll-like receptors. Trends Mol Med 2007, 13(11):460-469.
20. Kaisho T., Akiro Sh. Toll-like receptor function and signalling. J Allergy Clin Immunol 2006, 117:979-987.
21. Takeda K., Akiro Sh. TLR signalling pathways. Semin Immunol 2004, 16:3-9.
22. Salaun B., Romero P., Lebecque S. Toll-like receptors' two-edged sword: when immunity meets apoptosis. Eur J Immunol 2007, 37:3311-3318.
23. Cook D.N., Pisetsky D.S., Schwartz D.A. Toll-like receptors in the pathogenesis of human disease. Nat Immunol 2004, 5(10):975-979.
24. Nieters A., Beckmann L., Deeg E., Becker N. Gene polymorphisms in Toll-like receptors, interleukin-10 and interleukin-10 receptor alpha and lymphoma risk. Genes Immun 2006, 7(8):615-624.
25. Harmey J.H., Bucana C.D., Lu W., et al. Lipopolysaccharide-induced metastatic growth is associated with increased angiogenesis, vascular permeability and tumor cell invasion. Int J Cancer 2002, 101(5):415-422.
26. Andreani V., Gatti G., Simonella L., Rivero V., Maccioni M. Activation of Toll-like receptor 4 on tumor cells in vitro inhibits subsequent tumor growth in vivo. Cancer Res 2007, 67:10519-10527.
27. Kelly M.G., Alvero A.B., Chen R., et al. TLR-4 signaling promotes tumor growth and paclitaxel chemoresistance in ovarian cancer. Cancer Res 2006, 66:3859-3868.
28. Shen W., Waldschemidt M., Zhao X., Ratilff T., Krieg A.M. Antitumor Mechanisms of oligodeoxynucleotides with CpG and polyG motifs in murine prostate cancer cells: decrease of NF-kB and AP-1 binding activities and induction of apoptosis. Antisense Nucl Drug Dev 2002, 12:155-164.
29. Jiang Q., Wei H., Tian Zh. Poly I:C enhances cycloheximide-induced apoptosis of tumor cells through TLR3 pathway. BMC Cancer 2008, 8:12.
30. Merrell M.A., Ilvesaro J.M., Lehtonen N., et al. Toll-like receptor 9 agonists promote cellular invasion by increasing matrix metalloproteinase activity. Mol Cancer Res 2006, 4:437-447.
31. Droemann D., Albrecht D., Gerdes J., et al. Human lung cancer cells express functionally active Toll-like receptor 9. Resp Res 2005, 6:1-10.
32. Bourke E., Bosisio D., Golay J., Polentarutti N., Mantovani A. The Toll-like receptor repertoire of human B lymphocytes: inducible and selective expression of TLR9 and TLR10 in normal and transformed cells. Blood 2003, 102:956-963.
33. Chiron D., Bekeredjian-Ding I., Pellat-Deceunynck C., Bataille R., Jego G. Toll-like receptors: lessons to learn from normal and malignant B cells. Blood 2008, 112:2205-2213.
34. Bernasconi N.L., Onai N., Lanzavecchia A. A role for Toll-like receptors in acquired immunity: up-regulation of TLR9 by BCR triggering in naïve B cells and constitutive expression in memory B cells. Blood 2003, 101:4500-4504.
35. Bernasconi N.L., Onai N., Lanzavecchia A. Maintenance of serological memory by polyclonal activation of human memory B cells. Science 2002, 298:2199-2202.
36. Dorner M., Brandt S., Tinguely M., et al. Plasma cell toll-like receptor (TLR) expression differs from that of B cells, and plasma cell TLR triggering enhances immunoglobulin production. Immunology 2009, 128:573-579.
37. Yu L., Chen Sh. Toll-like receptors expressed in tumour cells: targets for therapy. Cancer Immunol Immunother 2008, 57:1271-1278.
38. Grandjenette C., Kennel A., Faure G.C., Bene M.C., Feugier P. Expression of functional Toll-like receptors by B-chronic lymphocytic leukemia cells. Haematologica 2007, 92:1279-1281.
39. Corthals S.L., Wynne K., She K., et al. Differential immune effects mediated by Toll-like receptors stimulation in precursor B-cell acute lymphocytic leukemia. Brit J Haematol 2005, 132:452-458.
40. Jahrsdorfer B., Muhlenhoff L., Blackwell S.E., et al. B-cell lymphomas differ in their responsiveness to CpG oligodeoxynucleotides. Clin Cancer Res 2005, 11:1490-1499.
41. Assaf A., Esteves H., Curnow S.J., Browning M.J. A threshold level of TLR9 mRNA predicts cellular responsiveness to CpG-ODN in haematological and non-haematological tumour cell lines. Cell Immunol 2009, 259(1):90-99.
42. Uchiyama H., Barut B.A., Mohrbacher A.F., Chauhan D., Anderson K.C. Adhesion of human myeloma-derived cell lines to bone marrow stromal cells stimulates interleukin-6 secretion. Blood 1993, 82:3712-3720.
43. Lokhorst H.M., Lamme T., de Smet K.S., de Weger R.A., van Oers R., Bloem A.C. Primary tumor cells of myeloma patients induce interleukin-6 secretion in long-term bone marrow cultures. Blood 1994, 84:2269-2277.
44. Gupta D., Treon S.P., Shima Y., et al. Adherence of multiple myeloma cells to bone marrow stromal cells upregulates vascular endothelial growth factor secretion: therapeutic applications. Leukemia 2001, 15:1950-1961.
45. Bisping G., Leo R., Wenning D., et al. Paracrine interactions of basic fibroblast growth factor and interleukin-6 in multiple myeloma. Blood 2003, 101:2775-2783.
46. Landowski T.H., Olashaw N.E., Agrawal D., Dalton W.S. Cell adhesion-mediated drug resistance (CAM-DR) is associated with activation of NF-κB (RelB/p50) in myeloma cells. Oncogene 2003, 22:2417-2421.
47. Keats J.J., Fonseca R., Chesi M., et al. Promiscuous mutations activate the non-canonical NF-kB pathway in multiple myeloma. Cancer Cell 2007, 12:131-144.
48. Demchenko Y.N., Glebov O.K., Zingone A., Keats J.J., Bergsagel P.L., Kuehl W.M. Classical and/or alternative NFκB pathway activation in multiple myeloma. Blood 2010, 115(17):3541-3552.
49. Hanten J.A., Vasilakos J.P., Riter Ch.L., et al. Comparison of human B cell activation by TLR7 and TLR9 agonists. BMC Immunol 2008, 9:39.
50. Pasare Ch, Medzhitov R. Control of B cell responses by Toll-like receptors. Nature 2005, 438:364-368.
51. Calame K. Activation-dependent induction of Blimp-1. Curr Opin Immunol 2008, 20:259-264.
52. Shapiro-Shelef M., Calame K. Regulation of plasma cell development. Nature 2005, 5:230-242.
53. Shapiro-Shelef M., Lin K.I., Savitsky D., Liao J., Calame K. Blimp-1 is required for maintenance of long-lived plasma cells in the bone marrow. J Exp Med 2005, 202:1471-1476.
54. Guay H.M., Andreyeva T.A., Garcea R.L., Welsh R.M., Szomolanyi-Tsuda E. MyD88 is required for the formation of long-term humoral immunity to virus infection. J Immunol 2007, 178:5124-5131.
55. Wolska A., Lech-Maranda E., Robak T. Toll-like receptors and their role in hematologic malignancies. Curr Mol Med 2009, 9(3):324-335.
56. Alexandrakis M.G., Passam F.H., Sfiridaki K., et al. Interleukin-18 in multiple myeloma patients: serum levels in relation to response to treatment and survival. Leukemia Res 2004, 28:259-266.
57. Kawano M.M., Ishikawa H., Tsuyama N., et al. Growth mechanism of human myeloma cells by interleukin-6. Int J Hematol 2002, 76 Supplement I.
58. Puthier D., Bataille R., Amiot M. IL-6 up-regulates Mcl-1 in human myeloma cells through JAK/STAT rather than Ras/MAP kinase pathway. Eur J Immunol 1999, 29:3945-3950.
59. Hardin J., MacLeod S., Grigorieva L., et al. Interleukin-6 prevents dexamethasone-induced myeloma cell death. Blood 1994, 84(9):3063-3070.
60. Chauhan Dh., Kharbanda S., Ogata A., et al. Interleukin-6 inhibits Fas-induced apoptosis and stress-activated protein kinase activation in multiple myeloma cells. Blood 1997, 89(1):227-234.
61. Frassanito M.A., Cusmai A., Iodice G., Dammacco F. Autocrine interleukin-6 production and highly malignant multiple myeloma: relation with resistance to drug-induced apoptosis. Blood 2001, 97:483-489.
62. Treon S.P., Anderson K.C. Interleukin-6 in multiple myeloma and related plasma cell dyscrasias. Curr Opin Hematol 1998, 5:42-48.
63. Gougelet A.L., Mansuy A., Blay J.Y., Alberti L., Vermot-Desroches C. Lymphoma and myeloma cell resistance to cytotoxic agents and ionizing radiations is not affected by exposure to anti-IL-6 antibody. PLoS ONE 2009, 4(11):e8026.
64. Spets H., Jernberg-Wiklund H., Sambade C., Söderberg O., Nilsson K. The effect on growth and survival of IL-6 can be dissociated in the U-266-1970/U-266-1984 and HL407E/HL407L human multiple myeloma cell lines. Br J Haematol 1997, 98:126-133.
65. Fukada T., Hibi M., Yamanaka Y., et al. Two signals are necessary for cell proliferation induced by a cytokine receptor gp130: involvement of Stat-3 in anti-apoptosis. Immunity 1996, 5:449-460.
66. Ogata A., Chauhan Dh, Urashima M., Teoh G., Treon S.P., Anderson K.C. Blockade of mitogen-activated protein kinase cascade signalling in interleukin 6-independent multiple myeloma cells. Clin Cancer Res 1997, 3:1017-1022.
67. Ogata A., Chauhan Dh, Teoh G., et al. IL-6 triggers cell growth via the Ras-dependent mitogen-activated protein kinase cascade. J Immunol 1997, 159(221):2-2221.
68. Iankov I., Atanasova G., Praskova M., et al. Bacterial lipopolysacharide induces proliferation of IL-6-dependent plasmacytoma cells by MAPK pathway activation. Immunobiology 2004, 208:445-454.
69. Rawstron A.C., Fenton J.A.L., Ashcroft J., et al. The interleukin-6 receptor alpha-chain (CD126) is expressed by neoplastic but not normal plasma cells. Blood 2000, 96:3880-3886.
70. Chiron D., Pellat-Deceunynck C., Amiot M., Bataille R., Jego G. TLR3 ligand induces NF-κB activation and various fates of multiple myeloma cells depending on IFN-α production. J Immunol 2009, 182:4471-4478.
71. Nishikori M. Classical and alternative NF-kB activation pathways and their roles in lymphoid malignancies. J Clin Exp Hematopathol 2005, 45:15-24.
72. Matsui W., Ann Huff C., Vala M., Barber J., Smith B.D., Jones R.J. Anti-tumour activity of interferon-alpha in multiple myeloma: role of interleukin 6 and tumor cell differentiation. Brit J Haematol 2003, 121:251-258.
73. Xu D., Erickson S., Szeps M.L., et al. Interferon alpha down-regulates telomerase reverse transcriptase and telomerase activity in human malignant and nonmalignant hematopoietic cells. Blood 2000, 96:4313-4318.
74. Liu P., Oken M., Ness B.V. Interferon-a protects myeloma cell lines from dexamethasone-induced apoptosis. Leukemia 1999, 13:473-480.
75. Bekisz J., Baron S., Balinsky C., Morrow A., Zoon K.C. Anti-proliferative properties of type I and type II interferon. Pharmaceuticals 2010, 3:994-1015.
76. Ratta M., Fagnoni F., Curti A., et al. Dendritic cells are functionally defective in multiple myeloma: the role of interleukin-6. Blood 2002, 100:230-237.
77. Maki G., Hayes G.M., Naji A., et al. NK resistance of tumor cells from multiple myeloma and chronic lymphocytic leukemia patients: implication of HLA-G. Leukemia 2008, 22:998-1006.
78. Prabhala R.H., Neri P., Bae J.E., et al. Dysfunctional T regulatory cells in multiple myeloma. Blood 2006, 107:301-304.
79. Yi Q., Dabadghao S., Sterborg A.Ö., Bergenbrant S., Holm G. Myeloma bone marrow plasma cells: evidence for their capacity as antigen-presenting cells. Blood 1997, 90(5):1960-1967.
80. Chauhan Dh., Singh A.V., Brahmandam M., et al. Functional interaction of plasmacytoid dendritic cells with multiple myeloma cells: a therapeutic target. Cancer Cell 2009, 16:309-323.
81. Zhan F., Huang Y., Colla S., et al. The molecular classification of multiple myeloma. Blood 2006, 108(6):2020-2028.
82. Tamura T., Yanai H., Savitsky D., Taniguchi T. The IRF family transcription factors in immunity and oncogenesis. Annu Rev Immunol 2008, 26:535-584.
83. Savitsky D., Tamura T., Yanai H., Taniguchi T. Regulation of immunity and oncogenesis by the IRF transcription factor family. Cancer Immunol Immunother 2010, 59:489-510.
84. Grote K., Schuett H., Salguero G., et al. Toll-like receptor 2/6 stimulation promotes angiogenesis via GM-CSF as a potential strategy for immune defense and tissue regeneration. Blood 2010, 115:2543-2552.
85. Harmey J.H., Bucana C.D., Lu W., et al. Lipopolysaccaride-induced metastatic growth is associated with increased angiogenesis, vascular permeability and tumor cell invasion. Int J Cancer 2002, 101:415-422.
86. Kleinman M.E., Yamada K., Takeda A., et al. Sequence-and target-independent angiogenesis suppression by siRNA via TLR3. Nature 2008, 452(3):591-598.
87. Korherr Ch., Gille H., Schafer R., et al. Identification of proangiogenic genes and pathways by high-throughput functional genomics: TBK1 and the IRF3 pathway. PNAS 2006, 103(11):4240-4245.
88. Asosingh K., De Raeve H., de Ridder M., et al. Role of the hypoxic bone marrow microenvironment in 5T2MM murine myeloma tumor progression. Haematologica 2005, 90:810-817.
89. Hu Y., Kirito K., Yoshida K., et al. Inhibition of hypoxia-inducible factor-1 function enhances the sensitivity of multiple myeloma cells to melphalan. Mol Cancer Ther 2009, 8(8):2329-2338.
90. Colla S., Storti P., Donofrio G., et al. Low bone marrow oxygen tension and hypoxia-inducible factor-1a overexpression characterize patients with multiple myeloma: role on the transcriptional and proangiogenic profiles of CD138+ cells. Leukemia 2010, 10.1038/leu.2010.193.
91. Paone A., Galli R., Gabellini Ch., et al. Toll-like receptor 3 regulates angiogenesis and apoptosis in prostate cancer cell lines through hypoxia inducible factor-1α. Neoplasia 2010, 12(7):539-549.
92. Zinkernagel A.S., Johnson R.S., Nizet V. Hypoxia inducible factor (HIF) function in innate immunity and infection. J Mol Med 2007, 85:1339-1346.
93. Nicholas S.A., Sumbayev V.V. The involvement of hypoxia-inducible factor 1 alpha in Toll-like receptor 7/8-mediated inflammatory response. Cell Res 2009, 19:973-983.
94. Lall H., Coughlan K., Sumbayev V.V. HIF-1α protein is an essential factor for protection of myeloid cells against LPS-induced depletion of ATP and apoptosis that supports Toll-like receptor 4-mediated production of IL-6. Mol Immunol 2008, 45:3045-3049.
95. Mitsiades C.S., Mitsiades N.S., McMullan C.J., et al. Anti-myeloma activity of heat shock protein-90 inhibition. Blood 2006, 107:1092-1100.
96. Okawa Y., Hideshima T., Steed P., et al. SNX-2112, a selective Hsp90 inhibitor, potently inhibits tumor cell growth, angiogenesis, and osteoclastogenesis in multiple myeloma and other hematologic tumors by abrogating signaling via Akt and ERK. Blood 2009, 113:846-855.
97. Kuhlicke J., Frick J.S., Morote-Garcia J.C., Rosenberger P., Eltzschig H.K. Hypoxia inducible factor (HIF)-1 coordinates induction of Toll-like receptors TLR2 and TLR6 during hypoxia. PLoS One 2007, 2(12):e1364.
98. Nemeth K., Mayer B., Mezey E. Modulation of bone marrow stromal cell functions in infectious diseases by toll-like receptor ligands. J Mol Med 2010, 88:5-10.
99. Bandholtz L., Guo Y., Palmberg C., et al. Hsp90 binds CpG oligonucleotides directly: implications for hsp90 as a missing link in CpG signaling and recognition. Cell Mol Life Sci 2003, 60(2):422-429.
100. De Nardo D., Masendycz P., Ho S., et al. A central role for the Hsp90.Cdc37 molecular chaperone module in interleukin-1 receptor-associated-kinase-dependent signaling by Toll-like receptors. J Biol Chem 2005, 280(11):9813-9822.
101. Steeve K.T., Marc P., Sandrine Th., Dominique H., Yannick F. IL-6, RANKL, TNF-alpha/IL-1: interrelations in bone resorption pathophysiology. Cytokine Growth F Rev 2004, 15:49-60.
102. Teitelbaum S.L. Bone resorption by osteoclasts. Science 2000, 289:1504-1508.
103. Chang E.J., Kim H.J., Ha J., et al. Hyaluronan inhibits osteoclast differentiation via Toll-like receptor 4. J Cell Sci 2007, 120:166-176.
104. Arai F., Miyamoto T., Ohneda O., et al. Commitment and differentiation of osteoclast precursor cells by the sequential expression of c-Fms and receptor activator of nuclear factor kB (RANK) receptors. J Exp Med 1999, 190(12):1741-1754.
105. Kikuchi T., Matsuguchi T., Tsuboi N., et al. Gene expression of osteoclast differentiation factor is induced by lipopolysaccharide in mouse osteoblasts via Toll-like receptors. J Immunol 2001, 166:3574-3579.
106. Hou L., Sasaki H., Stashenko Ph. Toll-like receptor 4-deficient mice have reduced bone destruction following mixed anaerobic infection. Infect Immun 2000, 68:4681-4687.
107. Zou W., Amcheslavsky A., Bar-Shavit Z. CpG oligodeoxynucleotides modulate the osteoclastogenic activity of osteoblasts via Toll-like receptor 9. J Biol Chem 2003, 278:16732-16740.
108. Takami M., Kim N., Rho J., Choi Y. Stimulation by toll-like receptors inhibits osteoclast differentiation. J Immunol 2002, 169:1516-1523.
109. Rock K.L., Kono H. The inflammatory response to cell death. Annu Rev Pathol Mech Dis 2008, 3:99-126.
110. Beg A.A. Endogenous ligands of Toll-like receptors: implications for regulating inflammatory and immune responses. Trends Immunol 2002, 23:509-511.
111. Matzinger P. The danger model: a renewed sense of self. Science 2002, 296:301-305.
112. Vacca A., Ribatti D., Presta M., et al. Bone marrow neovascularization, plasma cell angiogenic potential, and matrix metalloproteinase-2 secretion parallel progression of human multiple myeloma. Blood 1999, 93:3064-3073.
113. Ria R., Vacca A., Ribatti D., Di Raimondo F., Merchionne F., Dammacco F. αvβ3 Integrin engagement enhances cell invasiveness in human multiple myeloma. Haematologica 2002, 87:836-845.
114. Scheibner K.A., Lutz M.A., Boodoo S., Fenton M.J., Powell J.D., Horton M.R. Hyaluronan fragments act as an endogenous danger signal by engaging TLR2. J Immunol 2006, 177:1272-1281.
115. Okamura Y., Watari M., Jerud E.S., et al. The extra domain A of fibronectin activates Toll-like receptor 4. J Biol Chem 2001, 276(13):10229-10233.
116. Mantovani A., Garlanda C. Inflammation and multiple myeloma: the Toll connection. Leukemia 2006, 20:937-938.
117. Park J.S., Gamboni-Robertson F., He Q., et al. High mobility group box 1 protein interacts with multiple Toll-like receptors. Am J Physiol Cell Physiol 2006, 290:C917-C924.
118. Park J.S., Svetkauskaite D., He Q., et al. Involvement of Toll-like receptors 2 and 4 in cellular activation by high mobility group box 1 protein. J Biol Chem 2004, 279(9):7370-7377.
119. Nimmanapalli R., Gerbino E., Dalton W.S., Gandhi V., Alsina M. HSP70 inhibition reverses cell adhesion mediated and acquired drug resistance in multiple myeloma. Brit J Haematol 2008, 142:551-561.
120. Gramenzil A., Buttinol I., D'Avanzol B., Negri E., Franceschi S., Vecchia C.L. Medical history and the risk of multiple myeloma. Brit J Cancer 1991, 63:769-772.
121. Brown L.M., Gridley G., Check D., Landgren O. Risk of multiple myeloma and monoclonal gammopathy of undetermined significance among white and black male United States veterans with prior autoimmune, infectious, inflammatory, and allergic disorders. Blood 2008, 111:3388-3394.
122. Sjak-Shie N.N., Vescio R.A., Berenson J.R. HHV-8 infection and multiple myeloma. J Leukocyte Biol 1999, 66:357-360.
123. Mikala G., Xie J., Berencsi G., et al. Human herpesvirus 8 in hematologic diseases. Pathol Oncol Res 1999, 5(1).
124. Lagos D., Vart R.J., Gratrix F., et al. Toll-like receptor 4 mediates innate immunity to Kaposi sarcoma herpesvirus. Cell Host Microbe 2008, 4:470-483.
125. Guo-qing W., Mao-fang L., He H., Zhen C. Human cytomegalovirus protects multiple myeloma cell line KM3 from apoptosis induced by growth factor withdrawal. Chin Med J 2004, 117(6):903-907.
126. Coussens L.M., Werb Z. Inflammation and cancer. Nature 2002, 420(6917):860-867.
127. Chen R., Alvero A.B., Silasi D.A., Mor G. Inflammation, cancer and chemoresistance: taking advantage of toll-like receptor signaling pathway. Am J Reprod Immunol 2007, 57:93-107.
128. Pikarsky E., Porat R.M., Stein I., et al. NF-kB functions as a tumour promoter in inflammation-associated cancer. Nature 2004, 431:461-466.
129. Feinman R., Koury J., Thames M., Barlogie B., Epstein J., Siegel D.S. Role of NF-kappa B in the rescue of multiple myeloma cells from glucocorticoid-induced apoptosis by Bcl-2. Blood 1999, 93:3044-3052.
130. Kanzler H., Barrat F.J., Hessel E.M., Coffman R.L. Therapeutic targeting of innate immunity with Toll-like receptor agonists and antagonists. Nat Med 2007, 13(5):552-559.
131. Spaner D.E., Masellis A. Toll-like receptor agonists in the treatment of chronic lymphocytic leukemia. Leukemia 2007, 21:53-60.
132. Qian J., Hong S., Wang S., et al. Myeloma cell line derived, pooled heat shock proteins as a universal vaccine for immunotherapy of multiple myeloma. Blood 2009, 114:3880-3889.
133. Chen H., Li M., Campbell R.A., et al. Interference with nuclear factor kappa B and c-Jun NH2-terminal kinase signaling by TRAF6C small interfering RNA inhibits myeloma cell proliferation and enhances apoptosis. Oncogene 2006, 25:6520-6527.
134. Hideshima T., Chauhan Dh., Richardson P., et al. NFκB as a therapeutic target in multiple myeloma. J Biol Chem 2002, 277(19):16639-16647.
135. Luke A.J.O. SIGIRR puts the brakes on Toll-like receptors. Nat Immunol 2003, 4:823-824.
136. Wald D., Qin J., Zhao Zh., et al. SIGIRR, a negative regulator of Toll-like receptor-interleukin 1 receptor signaling. Nat Immunol 2003, 4:920-927.
137. Tomic J., White D., Shi Y., et al. Sensitization of IL-2 signaling through TLR-7 enhances B lymphoma cell immunogenicity. J Immunol 2006, 176:3830-3839.
138. Muzio M., Scielzo C., Bertilaccio M.T.S., Frenquelli M., Ghia P., Caligaris-Cappio F. Expression and function of toll like receptors in chronic lymphocytic leukaemia cells. Exp Hematol 2008, 28:558-568.
139. Jahrsdörfer B., Wooldridge J.E., Blackwell S.E., et al. Immunostimulatory oligodeoxynucleotides induce apoptosis of B cell chronic lymphocytic leukemia cells. J Leukocyte Biol 2005, 77:378-387.
140. Jahrsdörfer B., Hartmann G., Racila E., et al. CpG DNA increases primary malignant B cell expression of costimulatory molecules and target antigens. J Leukocyte Biol 2001, 69:81-88.
141. Secchiero P., Melloni E., Tiribelli M., Gonelli A., Zauli G. Combined treatment of CpG-oligodeoxynucleotide with Nutlin-3 induces strong immune stimulation coupled to cytotoxicity in B-chronic lymphocytic leukemic (B-CLL) cells. J Leukocyte Biol 2008, 83:434-437.
142. Shi Y., White D., He L., Miller R.L., Spaner D.E. Toll-like receptor-7 tolerizes malignant B cells and enhances killing by cytotoxic agents. Cancer Res 2007, 67(4):1823-1831.
143. Spaner D.E., Shi Y., White D., et al. Immunomodulatory effects of Toll-like receptor-7 activation on chronic lymphocytic leukemia cells. Leukaemia 2006, 20:286-295.
144. Corthals S.L., Wynne K., She K., et al. Differential immune effects mediated by Toll-like receptors stimulation in precursor B-cell acute lymphoblastic leukaemia. Brit J Haematol 2005, 132:452-458.
145. Reid G.S., She K., Terrett L., Food M.R., Trudeau J.D., Schultz K.R. CpG stimulation of precursor B-lineage acute lymphoblastic leukemia induces a distinct change in costimulatory molecule expression and shifts allogeneic T cells toward a Th1 response. Blood 2005, 105(9):3641-3647.